World Health Organization Available from: http://www.ipubli.inserm.fr/bitstream/handle, 156 p. 3. 102.pdf [Internet]. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer, pp.1803-1807, 1997. ,
ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer, Journal of Clinical Oncology, vol.24, issue.33, pp.5313-5340, 2006. ,
DOI : 10.1200/JCO.2006.08.2644
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer, Breast Cancer Research, vol.15, issue.1, p.68, 2010. ,
DOI : 10.1038/nm0809-842
Luminal breast cancer: from biology to treatment, Nature Reviews Clinical Oncology, vol.57, issue.9, 2013. ,
DOI : 10.1038/nrclinonc.2012.61
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma, Modern Pathology, vol.193, issue.2, 2006. ,
DOI : 10.1002/1096-9896(2000)9999:9999<::AID-PATH752>3.0.CO;2-V
The estrogen receptor: a model for molecular medicine, Clin Cancer Res Off J Am Assoc Cancer Res, vol.9, issue.6, pp.1980-1989, 2003. ,
Remarks on Oöphorectomy in the Treatment of Cancer of the Breast, Br Med J. 1899 Feb, vol.41, pp.257-62, 1988. ,
Landmark article Sept 8 An ovarian hormone. Preliminary report on its localization, extraction and partial purification, and action in test animals, pp.2681-2684, 1923. ,
Estrogen receptors and breast cancer response to adrenalectomy. Natl Cancer Inst Monogr, pp.55-70, 1971. ,
Specific progesterone receptors in human breast cancer, Steroids, vol.25, issue.4, 1975. ,
DOI : 10.1016/0039-128X(75)90027-6
The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro, Biochem Biophys Res Commun Feb, vol.4243, issue.1, pp.122-128, 1998. ,
Modulation of Estrogen Receptor Alpha Activity and Expression During Breast Cancer Progression, Vitam Horm, vol.93, pp.135-60, 2013. ,
DOI : 10.1016/B978-0-12-416673-8.00004-6
URL : https://hal.archives-ouvertes.fr/hal-00874313
A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples, Human Pathology, vol.26, issue.3, pp.291-295, 1995. ,
DOI : 10.1016/0046-8177(95)90060-8
Oestrogen receptors alpha and beta differ in normal human breast and breast carcinomas, The Journal of Pathology, vol.97, issue.4, pp.450-457, 2002. ,
DOI : 10.1038/bjc.1992.122
Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Sp gamma in frozen sections or cytosol-based ligand-binding assays. Cancer, pp.2514-2523, 1996. ,
Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients, British Journal of Cancer, vol.74, issue.9, pp.1445-51, 1996. ,
DOI : 10.1038/bjc.1996.563
Estrogen Receptor Analysis for Breast Cancer, Advances in Anatomic Pathology, vol.12, issue.1, pp.10-19, 2005. ,
DOI : 10.1097/00125480-200501000-00003
Immunohistochemical Detection Using the New Rabbit Monoclonal Antibody SP1 of Estrogen Receptor in Breast Cancer Is Superior to Mouse Monoclonal Antibody 1D5 in Predicting Survival, Journal of Clinical Oncology, vol.24, issue.36, pp.5637-5681, 2006. ,
DOI : 10.1200/JCO.2005.05.4155
Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B, EMBO J, vol.9, issue.5, pp.1603-1617, 1990. ,
Up-Regulation of the Progesterone Receptor (PR)-C Isoform in Laboring Myometrium by Activation of Nuclear Factor-??B May Contribute to the Onset of Labor through Inhibition of PR Function, Molecular Endocrinology, vol.20, issue.4, pp.764-75, 2006. ,
DOI : 10.1210/me.2005-0242
Progestin-mediated activation of MAPK and AKT in nuclear progesterone receptor negative breast epithelial cells: The role of membrane progesterone receptors, Gene, vol.591, issue.1, pp.6-13, 2016. ,
DOI : 10.1016/j.gene.2016.06.044
Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies, PLoS Medicine, vol.12, issue.5, p.1000279, 2010. ,
DOI : 10.1371/journal.pmed.1000279.s011
Antiestrogenic Effect of R5020, a Synthetic Progestin in Human Breast Cancer Cells in Culture*, The Journal of Clinical Endocrinology & Metabolism, vol.56, issue.6, pp.1124-1154, 1983. ,
DOI : 10.1210/jcem-56-6-1124
Mechanisms of Cyclin-Dependent Kinase Inactivation by Progestins, Molecular and Cellular Biology, vol.18, issue.4, pp.1812-1837, 1998. ,
DOI : 10.1128/MCB.18.4.1812
Progesterone Receptor Inhibits Proliferation of Human Breast Cancer Cells via Induction of MAPK Phosphatase 1 (MKP-1/DUSP1), Journal of Biological Chemistry, vol.169, issue.50, pp.43091-102, 2011. ,
DOI : 10.1074/jbc.M109.021469
Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures, Breast Cancer Research and Treatment, vol.7, issue.4, pp.415-447, 2012. ,
DOI : 10.1371/journal.pone.0035859
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3818141/pdf
Progesterone receptor modulates ER?? action in breast cancer, Nature, vol.27, issue.7560, pp.313-320, 2015. ,
DOI : 10.1200/JCO.2008.18.1370
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650274/pdf
Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases, Journal of Clinical Oncology, vol.21, issue.10, pp.1973-1982, 2003. ,
DOI : 10.1200/JCO.2003.09.099
Comparison of different antibodies for detection of progesterone receptor in breast cancer, Steroids, vol.67, issue.9, pp.799-813, 2002. ,
DOI : 10.1016/S0039-128X(02)00039-9
The ErbB receptors and their role in cancer progression, Experimental Cell Research, vol.284, issue.1, pp.99-110, 2003. ,
DOI : 10.1016/S0014-4827(02)00099-X
: Directing Key Signaling Networks Throughout Life, Annual Review of Pharmacology and Toxicology, vol.44, issue.1, pp.195-217, 2004. ,
DOI : 10.1146/annurev.pharmtox.44.101802.121440
Timeline: The discovery of receptor tyrosine kinases: targets for cancer therapy, Nature Reviews Cancer, vol.4, issue.5, pp.361-70, 2004. ,
DOI : 10.1038/nrc1360
Strong Correlation between Results of Fluorescent In Situ Hybridization and Immunohistochemistry for the Assessment of the ERBB2 (HER-2/neu) Gene Status in Breast Carcinoma, Modern Pathology, vol.10, issue.Suppl. 1, 2000. ,
DOI : 10.1002/gcc.2870100303
Repeated observation of breast tumor subtypes in independent gene expression data sets, Proceedings of the National Academy of Sciences, vol.360, issue.9338, pp.8418-8441, 2003. ,
DOI : 10.1016/S0140-6736(02)11087-7
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proceedings of the National Academy of Sciences, vol.179, issue.1, pp.10869-74, 2001. ,
DOI : 10.1002/(SICI)1096-9896(199605)179:1<31::AID-PATH523>3.0.CO;2-O
HER2+ Breast Cancer, American Journal of Clinical Pathology, vol.129, issue.2, pp.263-73, 2008. ,
DOI : 10.1309/99AE032R9FM8WND1
Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation, International Journal of Cancer, vol.18, issue.1, pp.13-20, 1983. ,
DOI : 10.1177/28.8.7003001
Cell cycle analysis of a cell proliferationassociated human nuclear antigen defined by the monoclonal antibody Ki-67, J Immunol Baltim Md, vol.133, issue.4, pp.1710-1715, 1950. ,
The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins, The Journal of Cell Biology, vol.123, issue.3, pp.513-535, 1993. ,
DOI : 10.1083/jcb.123.3.513
The Ki-67 protein: From the known and the unknown, Journal of Cellular Physiology, vol.19, issue.31, pp.311-333, 2000. ,
DOI : 10.1093/ajcp/110.1.24
Proliferation Marker Ki-67 in Early Breast Cancer, Journal of Clinical Oncology, vol.23, issue.28, pp.7212-7232, 2005. ,
DOI : 10.1200/JCO.2005.07.501
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12???155 patients, British Journal of Cancer, vol.27, issue.10, pp.1504-1517, 2007. ,
DOI : 10.1002/1097-0142(19910115)67:2<421::AID-CNCR2820670217>3.0.CO;2-Q
Ki67 in breast cancer: prognostic and predictive potential, The Lancet Oncology, vol.11, issue.2, pp.174-83, 2010. ,
DOI : 10.1016/S1470-2045(09)70262-1
Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients, The Breast, vol.17, issue.4, 2008. ,
DOI : 10.1016/j.breast.2008.02.002
Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, Ann Oncol Off J Eur Soc Med Oncol, 2011. ,
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013, Annals of Oncology, vol.24, issue.9, pp.2206-2229, 2013. ,
DOI : 10.1093/annonc/mdt303
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009, Annals of Oncology, vol.20, issue.8, pp.1319-1348, 2009. ,
DOI : 10.1093/annonc/mdp322
Strategies for developing Ki67 as a useful biomarker in breast cancer, The Breast, vol.24, issue.2, pp.67-72, 2015. ,
DOI : 10.1016/j.breast.2015.07.017
The Urokinase Plasminogen Activator System: Role in Malignancy, Current Pharmaceutical Design, vol.10, issue.1, pp.39-49, 2004. ,
DOI : 10.2174/1381612043453559
Plasminogen activation and cancer, Thrombosis and Haemostasis, vol.93, issue.4, pp.676-81, 2005. ,
DOI : 10.1160/TH05-01-0054
Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1, Expert Review of Molecular Diagnostics, vol.10, issue.8, pp.1051-67, 2010. ,
DOI : 10.1586/erm.10.73
Cell Surface Remodeling by Plasmin: A New Function for an Old Enzyme, Journal of Biomedicine and Biotechnology, vol.41, issue.7, p.564259, 2012. ,
DOI : 10.1042/BJ20110129
URL : http://doi.org/10.1155/2012/564259
Fibrinolysis-independent role of plasmin and its activators in the haematopoietic recovery after myeloablation, Journal of Cellular and Molecular Medicine, vol.22, issue.11-12, 2009. ,
DOI : 10.1161/01.RES.81.5.829
Urokinase plasminogen activator receptor: a functional integrator of extracellular proteolysis, cell adhesion, and signal transduction, Semin Thromb Hemost, 2013. ,
Dynamic Assembly of the Urokinase-type Plasminogen Activator Signaling Receptor Complex Determines the Mitogenic Activity of Urokinase-type Plasminogen Activator, Journal of Biological Chemistry, vol.16, issue.17, pp.17449-57, 2005. ,
DOI : 10.1074/jbc.M101303200
Urokinase-induced signaling in human vascular smooth muscle cells is mediated by PDGFR-??, The EMBO Journal, vol.271, issue.10, pp.1787-97, 2005. ,
DOI : 10.1128/MCB.19.5.3727
URL : http://embojnl.embopress.org/content/embojnl/24/10/1787.full.pdf
uPAR regulates pericellular proteolysis through a mechanism involving integrins and fMLF-receptors, Thrombosis and Haemostasis, vol.109, issue.2, 2013. ,
DOI : 10.1160/TH12-08-0546
Biochemical properties of plasminogen activator inhibitor-1. Front Biosci Landmark Ed, pp.1337-61, 2009. ,
DOI : 10.2741/3312
Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes, The EMBO Journal, vol.16, issue.10, pp.2610-2630, 1997. ,
DOI : 10.1093/emboj/16.10.2610
Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene, pp.3097-104, 1998. ,
Activation of Pro-uPA Is Critical for Initial Escape from the Primary Tumor and Hematogenous Dissemination of Human Carcinoma Cells, Neoplasia, vol.13, issue.9, pp.806-827, 2011. ,
DOI : 10.1593/neo.11704
SK-216, an Inhibitor of Plasminogen Activator Inhibitor-1, Limits Tumor Progression and Angiogenesis, Molecular Cancer Therapeutics, vol.12, issue.11, 2013. ,
DOI : 10.1158/1535-7163.MCT-13-0041
URL : http://mct.aacrjournals.org/content/molcanther/12/11/2378.full.pdf
Protumorigenic Activity of Plasminogen Activator Inhibitor-1 Through an Antiapoptotic Function, JNCI: Journal of the National Cancer Institute, vol.104, issue.19, pp.1470-84, 2012. ,
DOI : 10.1093/jnci/djs377
Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer, pp.531-534, 1988. ,
DOI : 10.1002/1097-0142(19880801)62:3<531::aid-cncr2820620315>3.0.co;2-b
URL : http://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19880801)62:3<531::AID-CNCR2820620315>3.0.CO;2-B/pdf
Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination, J Clin Oncol Off J Am Soc Clin Oncol Feb, vol.1520, issue.4, pp.1000-1007, 2002. ,
Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res, pp.4617-4639, 2002. ,
Predictive Impact of Urokinase-Type Plasminogen Activator, Cancer Research, vol.64, issue.2, pp.659-64, 2004. ,
DOI : 10.1158/0008-5472.CAN-03-1820
URL : http://cancerres.aacrjournals.org/content/canres/64/2/659.full.pdf
High levels of uPA and PAI-1 predict a good response to anthracyclines, Breast Cancer Research and Treatment, vol.21, issue.6, pp.615-639, 2010. ,
DOI : 10.1200/JCO.2006.01.903
URL : https://hal.archives-ouvertes.fr/hal-00612980
Gene expression profiling predicts clinical outcome of breast cancer, Nature, vol.344, issue.6871, pp.530-536, 2002. ,
DOI : 10.1056/NEJM200102223440801
Erratum: Determining the influence of structure on hybridization using oligonucleotide arrays, Nature Biotechnology, vol.17, issue.10, pp.788-92, 1999. ,
DOI : 10.1038/13726
A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors, Clinical Cancer Research, vol.17, issue.18, pp.6012-6032, 2011. ,
DOI : 10.1158/1078-0432.CCR-11-0926
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer, New England Journal of Medicine, vol.351, issue.27, pp.2817-2843, 2004. ,
DOI : 10.1056/NEJMoa041588
A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogenreceptor-positive tumors, N Engl J Med Feb, vol.23320, issue.8, pp.479-84, 1989. ,
Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials, The Lancet, vol.364, issue.9437, pp.858-68, 2004. ,
DOI : 10.1016/S0140-6736(04)16981-X
Tamoxifen and Chemotherapy for Lymph Node-Negative, Estrogen Receptor-Positive Breast Cancer, JNCI Journal of the National Cancer Institute, vol.89, issue.22, pp.1673-82, 1997. ,
DOI : 10.1093/jnci/89.22.1673
URL : https://academic.oup.com/jnci/article-pdf/89/22/1673/7708589/89-22-1673.pdf
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor???Positive Breast Cancer, Journal of Clinical Oncology, vol.24, issue.23, pp.3726-3760, 2006. ,
DOI : 10.1200/JCO.2005.04.7985
Multigene prognostic tests in breast cancer: past, present, future, Breast Cancer Research, vol.26, issue.24 Suppl, p.11, 2015. ,
DOI : 10.1200/JCO.2007.14.4147
The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1???3 positive lymph nodes in an independent validation study, Breast Cancer Research and Treatment, vol.3, issue.2, pp.295-302, 2009. ,
DOI : 10.1093/jnci/94.2.116
URL : https://hal.archives-ouvertes.fr/hal-00478252
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes, Journal of Clinical Oncology, vol.27, issue.8, pp.1160-1167, 2009. ,
DOI : 10.1200/JCO.2008.18.1370
DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy, Journal of Clinical Oncology, vol.31, issue.22, pp.312783-90, 2013. ,
DOI : 10.1200/JCO.2012.46.1558
Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis, JNCI: Journal of the National Cancer Institute, vol.98, issue.4, pp.262-72, 2006. ,
DOI : 10.1093/jnci/djj052
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer, New England Journal of Medicine, vol.347, issue.25, pp.1999-2009, 2002. ,
DOI : 10.1056/NEJMoa021967
Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen, Annals of Oncology, vol.23, issue.11, pp.2866-73, 2012. ,
DOI : 10.1093/annonc/mds080
URL : https://academic.oup.com/annonc/article-pdf/23/11/2866/13786106/mds080.pdf
Agreement in Risk Prediction Between the 21-Gene Recurrence Score Assay (Oncotype DX(R)) and the PAM50 Breast Cancer Intrinsic Classifier?? in Early-Stage Estrogen Receptor-Positive Breast Cancer, The Oncologist, vol.17, issue.4, pp.492-500, 2012. ,
DOI : 10.1634/theoncologist.2012-0007
First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations, Breast Cancer Research and Treatment, vol.9, issue.6, pp.155-64, 2011. ,
DOI : 10.1186/1471-2164-9-394
Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer, Journal of Clinical Oncology, vol.29, issue.32, pp.4273-4281, 2011. ,
DOI : 10.1200/JCO.2010.31.2835
Predictive and Prognostic Value of the TauProtein in Breast Cancer, Anticancer Res, vol.35, issue.10, pp.5179-84, 2015. ,
Chromatin CKAP2, a New Proliferation Marker, as Independent Prognostic Indicator in Breast Cancer, PLoS ONE, vol.134, issue.6, p.98160, 2014. ,
DOI : 10.1371/journal.pone.0098160.t004
SerpinB3, a new prognostic tool in breast cancer patients treated with neoadjuvant chemotherapy, Breast Cancer Research and Treatment, vol.7, issue.3, 2012. ,
DOI : 10.1038/nrclinonc.2010.61
Both high expression of pyruvate kinase M2 and vascular endothelial growth factor-C predicts poorer prognosis in human breast cancer, Int J Clin Exp Pathol, vol.8, issue.7, pp.8028-8065, 2015. ,
New Findings on Breast Cancer Stem Cells: A Review, Journal of Breast Cancer, vol.18, issue.4, pp.303-315, 2015. ,
DOI : 10.4048/jbc.2015.18.4.303
URL : http://synapse.koreamed.org/Synapse/Data/PDFData/0096JBC/jbc-18-303.pdf
ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome, Cell Stem Cell, vol.1, issue.5, pp.555-67, 2007. ,
DOI : 10.1016/j.stem.2007.08.014
URL : https://hal.archives-ouvertes.fr/hal-01431968
Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, pp.15-20, 2005. ,
Most mammalian mRNAs are conserved targets of microRNAs, Genome Research, vol.19, issue.1, pp.92-105, 2009. ,
DOI : 10.1101/gr.082701.108
URL : http://genome.cshlp.org/content/19/1/92.full.pdf
MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy, Nature Reviews Cancer, vol.39, issue.12, pp.849-64, 2011. ,
DOI : 10.1038/ng2003
Causes and consequences of microRNA dysregulation in cancer, Nature Reviews Genetics, vol.124, issue.10, pp.704-718, 2009. ,
DOI : 10.4161/cc.7.6.5834
MicroRNAs in Cancer, Annual Review of Medicine, vol.60, issue.1, pp.167-79, 2009. ,
DOI : 10.1146/annurev.med.59.053006.104707
microRNAs in Cancer, Adv Cancer Res, vol.108, pp.113-57, 2010. ,
DOI : 10.1016/B978-0-12-380888-2.00004-2
MicroRNAs can generate thresholds in target gene expression, Nature Genetics, vol.43, issue.9, pp.854-863, 2011. ,
DOI : 10.1126/science.1137999
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163764/pdf
A systematic evaluation of miRNA:mRNA interactions involved in the migration and invasion of breast cancer cells, Journal of Translational Medicine, vol.11, issue.1, p.57, 2013. ,
DOI : 10.1016/j.tcb.2010.01.001
MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene, pp.5017-5039, 2007. ,
DOI : 10.1038/sj.onc.1210293
URL : http://www.nature.com/onc/journal/v26/n34/pdf/1210293a.pdf
Effect of microRNA-34a in cell cycle, differentiation, and apoptosis: A review, Journal of Biochemical and Molecular Toxicology, vol.115, issue.2, pp.79-86, 2012. ,
DOI : 10.1016/S0092-8674(03)01018-3
Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis, Mol Cell Proteomics MCP, vol.10, issue.8, pp.111-010462, 2011. ,
Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA, Breast Cancer Research and Treatment, vol.17, issue.11, pp.663-79, 2011. ,
DOI : 10.1038/cdd.2009.56
Restitution of Tumor Suppressor MicroRNAs Using a Systemic Nanovector Inhibits Pancreatic Cancer Growth in Mice, Molecular Cancer Therapeutics, vol.10, issue.8, pp.1470-80, 2011. ,
DOI : 10.1158/1535-7163.MCT-11-0152
miRNA-34 Prevents Cancer Initiation and Progression in a Therapeutically Resistant K-ras and p53-Induced Mouse Model of Lung Adenocarcinoma, Cancer Research, vol.72, issue.21, pp.5576-87, 2012. ,
DOI : 10.1158/0008-5472.CAN-12-2001
Dysregulation of MicroRNA-34a Expression in Head and Neck Squamous Cell Carcinoma Promotes Tumor Growth and Tumor Angiogenesis, PLoS ONE, vol.85, issue.5, p.37601, 2012. ,
DOI : 10.1371/journal.pone.0037601.s003
MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1. Oncogene, pp.4294-303, 2013. ,
DOI : 10.1038/onc.2012.432
MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1, Clinical and Experimental Medicine, vol.17, issue.9, pp.109-126, 2013. ,
DOI : 10.1158/1078-0432.CCR-10-3244
Downregulation of miR-34a in breast tumors is not associated with either p53 mutations or promoter hypermethylation while it correlates with metastasis, Medical Oncology, vol.377, issue.1, p.413, 2013. ,
DOI : 10.1016/j.bbrc.2008.09.086
Quantitative assessment of miR34a as an independent prognostic marker in breast cancer, British Journal of Cancer, vol.2, issue.1, pp.61-69, 2015. ,
DOI : 10.1038/onc.2012.432
MiR-34a Expression Has an Effect for Lower Risk of Metastasis and Associates with Expression Patterns Predicting Clinical Outcome in Breast Cancer, PLoS ONE, vol.69, issue.2, p.26122, 2011. ,
DOI : 10.1371/journal.pone.0026122.s004
Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management Available from, Breast Cancer Res BCR [Internet], vol.17, 2015. ,
Tumor Antigens Recognized by T Lymphocytes, Annual Review of Immunology, vol.12, issue.1, pp.337-65, 1994. ,
DOI : 10.1146/annurev.iy.12.040194.002005
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma, Science, vol.254, issue.5038, pp.1643-1650, 1991. ,
DOI : 10.1126/science.1840703
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity, Nature, vol.410, issue.6832, pp.1107-1118, 2001. ,
DOI : 10.1038/35074122
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome, Science, vol.313, issue.5795, pp.1960-1964, 2006. ,
DOI : 10.1126/science.1129139
Analysis of the T Cell Receptor Variability of Tumor-Infiltrating Lymphocytes in Colorectal Carcinomas, Tumor Biology, vol.19, issue.3, pp.205-217, 1998. ,
DOI : 10.1159/000030008
Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells, Cancer Immunology, Immunotherapy, vol.52, issue.7, pp.423-431, 2003. ,
DOI : 10.1007/s00262-003-0388-5
CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res, pp.3491-3495, 1998. ,
Histopathologic-Based Prognostic Factors of Colorectal Cancers Are Associated With the State of the Local Immune Reaction, Journal of Clinical Oncology, vol.29, issue.6, pp.610-618, 2011. ,
DOI : 10.1200/JCO.2010.30.5425
From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer, Current Opinion in Immunology, vol.25, issue.2, pp.261-268 ,
DOI : 10.1016/j.coi.2013.03.004
In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer, Journal of Clinical Oncology, vol.27, issue.35, pp.5944-51, 2009. ,
DOI : 10.1200/JCO.2008.19.6147
Towards the introduction of the ???Immunoscore??? in the classification of malignant tumours, The Journal of Pathology, vol.39, issue.2, pp.199-209 ,
DOI : 10.1016/j.immuni.2013.10.003
Identification of p62/SQSTM1 as a component of non-canonical Wnt VANGL2???JNK signalling in breast cancer, Nature Communications, vol.14, p.10318, 2016. ,
DOI : 10.1016/j.cub.2004.05.051
URL : https://hal.archives-ouvertes.fr/hal-01447570
Planar Cell Polarity Signaling: New Opportunities for Cancer Treatment. Trends Cancer, Feb, vol.13, issue.2, pp.113-138, 2017. ,
DOI : 10.1016/j.trecan.2017.01.001
WNT signalling pathways as therapeutic targets in cancer, Nature Reviews Cancer, vol.284, issue.1, pp.11-26 ,
DOI : 10.1074/jbc.M109.048884
A protein complex of SCRIB, NOS1AP and VANGL1 regulates cell polarity and migration, and is associated with breast cancer progression, Oncogene, vol.365, issue.32, pp.3696-708, 2009. ,
DOI : 10.1016/j.cell.2008.09.045
A noncanonical Frizzled2 pathway regulates epithelial-mesenchymal transition and metastasis. Cell, pp.844-56, 2014. ,
DOI : 10.1016/j.cell.2014.10.032
URL : https://doi.org/10.1016/j.cell.2014.10.032
Vangl1 and Vangl2: planar cell polarity components with a developing role in cancer, Endocrine Related Cancer, vol.21, issue.5, pp.345-356, 2014. ,
DOI : 10.1530/ERC-14-0141
URL : http://erc.endocrinology-journals.org/content/21/5/R345.full.pdf
Exosomes Mediate Stromal Mobilization of Autocrine Wnt-PCP Signaling in Breast Cancer Cell Migration, Cell, vol.151, issue.7, pp.1542-56, 2012. ,
DOI : 10.1016/j.cell.2012.11.024
Isolation and characterization of a novel human gene, VANGL1, as a therapeutic target for hepatocellular carcinoma, International Journal of Oncology, 2002. ,
DOI : 10.3892/ijo.20.6.1173
KITENIN increases invasion and migration of mouse squamous cancer cells and promotes pulmonary metastasis in a mouse squamous tumor model, FEBS Letters, vol.3, issue.4, pp.711-718, 2009. ,
DOI : 10.1038/nrc1209
KITENIN is associated with tumor progression in human gastric cancer, Anticancer Res, vol.30, issue.9, pp.3479-86, 2010. ,
Intravenous KITENIN shRNA Injection Suppresses Hepatic Metastasis and Recurrence of Colon Cancer in an Orthotopic Mouse Model, Journal of Korean Medical Science, vol.26, issue.11, pp.1439-1484, 2011. ,
DOI : 10.3346/jkms.2011.26.11.1439
Expression of KITENIN and its association with tumor progression in oral squamous cell carcinoma, Auris Nasus Larynx, vol.40, issue.2, 2013. ,
DOI : 10.1016/j.anl.2012.07.006
KAI1 COOH-Terminal Interacting Tetraspanin (KITENIN), a Member of the Tetraspanin Family, Interacts with KAI1, a Tumor Metastasis Suppressor, and Enhances Metastasis of Cancer, Cancer Research, vol.64, issue.12, pp.4235-4278, 2004. ,
DOI : 10.1158/0008-5472.CAN-04-0275
The Planar Cell Polarity Pathway Drives Pathogenesis of Chronic Lymphocytic Leukemia by the Regulation of B-Lymphocyte Migration, Cancer Research, vol.73, issue.5, pp.1491-501, 2013. ,
DOI : 10.1158/0008-5472.CAN-12-1752
REporting recommendations for tumour MARKer prognostic studies (REMARK), European Journal of Cancer, vol.41, issue.12, pp.387-91, 2005. ,
DOI : 10.1016/j.ejca.2005.03.032
Loss of antigenicity in stored sections of breast cancer tissue microarrays. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol, pp.667-72, 2004. ,
Assessment of problems in diagnostic and research immunohistochemistry associated with epitope instability in stored paraffin sections, Appl Immunohistochem Mol Morphol AIMM, vol.8, issue.4, pp.316-337, 2000. ,
Evaluation of Sampling Strategies for Modeling Survival of Uveal Malignant Melanoma, Investigative Opthalmology & Visual Science, vol.44, issue.8, pp.3288-93, 2003. ,
DOI : 10.1167/iovs.02-1328
Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System, Journal of Clinical Oncology, vol.25, issue.15, pp.2127-2159, 2007. ,
DOI : 10.1200/JCO.2006.10.3523
The impact of time-dependent bias in proportional hazards modelling, Statistics in Medicine, vol.5, issue.5, pp.6439-54, 2008. ,
DOI : 10.1007/978-1-4757-3294-8
Time-dependent bias was common in survival analyses published in leading clinical journals, Journal of Clinical Epidemiology, vol.57, issue.7, pp.672-82, 2004. ,
DOI : 10.1016/j.jclinepi.2003.12.008
The CONSORT Statement: revised recommendations for improving the quality of reports of parallel-group randomized trials, Explore N Y N, 2001. ,
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement, Epidemiology, vol.18, issue.6, pp.1495-1504, 2014. ,
DOI : 10.1097/EDE.0b013e3181577654
Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines, British Journal of Cancer, vol.40, issue.1, pp.173-80, 2009. ,
DOI : 10.3310/hta13050
Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers, JNCI Journal of the National Cancer Institute, vol.88, issue.20, pp.1456-66, 1996. ,
DOI : 10.1093/jnci/88.20.1456
Assessing the clinical impact of prognostic factors: when is " statistically significant " clinically useful?, Breast Cancer Res Treat, vol.52, pp.1-3305, 1998. ,
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers, JNCI Journal of the National Cancer Institute, vol.101, issue.21, pp.1446-52, 2009. ,
DOI : 10.1093/jnci/djp335
Prognosis and predictive values for clinical utility in breast cancer management], Oncotype DX TM MammaPrint Bull Cancer, vol.1102, issue.9, pp.719-748, 2015. ,
uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies, Breast Cancer Research, vol.108, issue.Suppl, p.428, 2014. ,
DOI : 10.1038/bjc.2013.62
Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review, Breast Cancer Research and Treatment, vol.63, issue.Suppl, pp.895-915 ,
DOI : 10.1136/jcp.2010.077578
Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial, European Journal of Cancer, vol.45, issue.7, pp.1201-1209, 1990. ,
DOI : 10.1016/j.ejca.2009.01.004
Clinical Application of the 70-Gene Profile: The MINDACT Trial, Journal of Clinical Oncology, vol.26, issue.5, pp.729-764, 2008. ,
DOI : 10.1200/JCO.2007.14.3222